

Announcement on Saliva SARS-CoV-2(2019-nCoV) Antigen Test Kit
(Nanocarbon Assay) 's efficacy against new SARS-CoV-2 variants - Special
report on **Omicron Variant (B.1.1.529)**

Coronavirus are enveloped RNA viruses that are distributed broadly among humans, birds and other mammals, that cause respiratory, enteric, hepatic, and neurologic diseases. Six coronavirus species are known to cause human disease. Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.

Recently, the newly emerged Omicron variant shows a greater number of mutations as compared to the Delta variant. The Omicron variant was first reported to WHO by South Africa on 24 November 2021 and since then, this variant has been detected in 9 other countries.

To ensure that WiseTest Saliva SARS-CoV-2(2019-nCoV) Antigen Test Kit (Nanocarbon Assay) can detect the new Omicron variant, WiseTest has conducted extensive in silico analysis of its test kit design and found out that its test kit can detect wild-type and Omicron form of recombinant N protein, RBD and spike equally well. Wet lab evaluation of our test kit design is currently undergoing. Nevertheless, we foresee that our kit will be able to detect the new Omicron variant.

Signed by



Xuefei Zhang
Executive director
GM of International Division



Tel: 0573-8445 8700 Fax: 0573-8445 7770 Mail: Zhangxf@jxwisetest.com

Add: 浙江省嘉兴市嘉善县西塘镇开源大道 268 号 F 幢 (314102)

(Building F, 268 Kaiyuan Avenue, Xitang Town, Jiashan County, Jiexing City, Zhejiang Province PRC (314102))